GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viva Biotech Holdings (FRA:VB0) » Definitions » Equity-to-Asset

Viva Biotech Holdings (FRA:VB0) Equity-to-Asset : 0.54 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Viva Biotech Holdings Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Viva Biotech Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2024 was €498.8 Mil. Viva Biotech Holdings's Total Assets for the quarter that ended in Dec. 2024 was €924.8 Mil. Therefore, Viva Biotech Holdings's Equity to Asset Ratio for the quarter that ended in Dec. 2024 was 0.54.

The historical rank and industry rank for Viva Biotech Holdings's Equity-to-Asset or its related term are showing as below:

FRA:VB0' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.46   Med: 0.5   Max: 0.94
Current: 0.54

During the past 9 years, the highest Equity to Asset Ratio of Viva Biotech Holdings was 0.94. The lowest was 0.46. And the median was 0.50.

FRA:VB0's Equity-to-Asset is ranked worse than
61.46% of 1505 companies
in the Biotechnology industry
Industry Median: 0.67 vs FRA:VB0: 0.54

Viva Biotech Holdings Equity-to-Asset Historical Data

The historical data trend for Viva Biotech Holdings's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viva Biotech Holdings Equity-to-Asset Chart

Viva Biotech Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only 0.46 0.49 0.46 0.50 0.54

Viva Biotech Holdings Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.45 0.50 0.53 0.54

Competitive Comparison of Viva Biotech Holdings's Equity-to-Asset

For the Biotechnology subindustry, Viva Biotech Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viva Biotech Holdings's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Viva Biotech Holdings's Equity-to-Asset falls into.


;
;

Viva Biotech Holdings Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Viva Biotech Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Equity to Asset (A: Dec. 2024 )=Total Stockholders Equity/Total Assets
=498.753/924.817
=0.54

Viva Biotech Holdings's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Equity to Asset (Q: Dec. 2024 )=Total Stockholders Equity/Total Assets
=498.753/924.817
=0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Viva Biotech Holdings  (FRA:VB0) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Viva Biotech Holdings Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Viva Biotech Holdings's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Viva Biotech Holdings Business Description

Traded in Other Exchanges
Address
735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318
Viva Biotech Holdings is an integrated drug discovery platform. The company's operating segment includes Drug discovery services and Contract Development Manufacture Organisation (CDMO) and commercialisation services. It generates maximum revenue from the Contract Development Manufacture Organisation (CDMO) and commercialisation services segment. The Contract Development Manufacture Organisation (CDMO) and commercialisation services segment include contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates, and formulations. Geographically, the company generates a majority of its revenue from the United States of America, and the rest from the European Union, Chinese Mainland, Africa, and other regions.

Viva Biotech Holdings Headlines

No Headlines